Ezetimibe ameliorates atherogenic lipids profiles, insulin resistance and hepatocyte growth factor in obese patients with hypercholesterolemia

Table 3 Laboratory findings before and after ezetimibe monotherapy and combined therapy

	Monotherapy	(n = 71)	Combined therapy	(n = 20)
Parameters	Pre	Post 6M	Pre	Post 6M
Body mass index (kg/m²)	28.2 ± 3.7	28.0 ± 3.8	27.2 ± 2.0	25.9 ± 1.6*
Waist circumference (cm)	94.6 ± 8.2	92.8 ± 8.6***	91.0 ± 5.6	88.3 ± 5.3**
Systolic blood pressure (mmHg)	130.1 ± 14.6	128.8 ± 13.2*	125.6 ± 13.8	121.8 ± 11.2
Diastolic blood pressure (mmHg)	77.3 ± 9.5	75.9 ± 10.6*	71.7 ± 8.2	69.5 ± 7.7
Total cholesterol (mg/dl)	237.9 ± 35.9	212.0 ± 33.0***	224.7 ± 27.8	192.2 ± 36.1*
LDL-cholesterol (mg/dl)	151.3 ± 28.6	132.4 ± 28.6***	132.1 ± 26.8	107.8 ± 30.5*
HDL-cholesterol (mg/dl)	51.9 ± 9.9	55.1 ± 9.4***	50.8 ± 11.9	53.3 ± 11.5***
Non HDL-cholesterol (mg/dl)	184.9 ± 31.7	155.6 ± 32.5***	174.6 ± 25.8	141.8 ± 32.2**
Triglycerides⁺ (mg/dl)	157.5	129.2***	210.9	155.3***
RLP-cholesterol⁺ (mg/dl)	6.3	4.7**	8.2	4.7***
Free fatty acid⁺ (mEq/l)	435.9	505.6*	435.4	429.7
Plasma glucose (mg/dl)	105.1 ± 27.9	102.6 ± 26.4*	109.3 ± 21.7	105.1 ± 15.9
Insulin⁺ (μU/ml)	12.1	9.6**	11.7	11.4
HOMA index⁺	3.0	2.4**	3.2	2.9
hsCRP⁺ (mg/dl)	807.0	883.7*	686.1	879.6*
Aldosterone (pg/dl)⁺	86.9	92.9*	101.6	110.8
HGF (ng/ml)	0.33 ± 0.07	0.31 ± 0.04*	0.31 ± 0.03	0.30 ± 0.02
Adiponectine (μg/ ml)⁺	2.51	2.56	2.49	2.47
EPA/AA⁺	0.29	0.28	0.39	0.40

*: p < 0.05, **: p < 0.01, ***: p < 0.001.
Data are means (SD), geometric mean and range. *: These variables are shown in the original scale after analysis using log (natural)-transformed values.
Abbreviations: RLP Remnant-like particle cholesterol, HOMA Homeostasis model assessment, HGF Hepatocyte growth factor, EPA/AA Eicosapentaenoic acid to arachidonic acid.

ISSN: 1476-511X